Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Saleh K, Daste A, Martin N, Pons-Tostivint E, Auperin A, Herrera-Gomez RG, Baste-Rotllan N, Bidault F, Guigay J, Le Tourneau C, Saada-Bouzid E, Even C.

Eur J Cancer. 2019 Sep 28;121:123-129. doi: 10.1016/j.ejca.2019.08.026. [Epub ahead of print]

PMID:
31574417
2.

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions.

Guigay J, Tahara M, Licitra L, Keilholz U, Friesland S, Witzler P, Mesía R.

Front Oncol. 2019 Aug 21;9:668. doi: 10.3389/fonc.2019.00668. eCollection 2019. Review.

3.

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.

Haddad R, Guigay J, Keilholz U, Clement PM, Fayette J, de Souza Viana L, Rolland F, Cupissol D, Geoffrois L, Kornek G, Licitra L, Melichar B, Ribaldo Nicolau U, Rauch D, Zanetta-Devauges S, Cohen EEW, Machiels JP, Tahara M, Vermorken J, Geng Y, Zografos E, Gauler T.

Oral Oncol. 2019 Oct;97:82-91. doi: 10.1016/j.oraloncology.2019.08.004. Epub 2019 Aug 23.

PMID:
31450171
4.

Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.

Saba NF, Blumenschein G Jr, Guigay J, Licitra L, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Brossart P.

Oral Oncol. 2019 Sep;96:7-14. doi: 10.1016/j.oraloncology.2019.06.017. Epub 2019 Jul 3.

5.

Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study.

Garrel R, Mazel M, Perriard F, Vinches M, Cayrefourcq L, Guigay J, Digue L, Aubry K, Alfonsi M, Delord JP, Lallemant B, Even C, Daurès JP, Landais P, Cupissol D, Alix-Panabières C.

Clin Chem. 2019 Oct;65(10):1267-1275. doi: 10.1373/clinchem.2019.305904. Epub 2019 Aug 6.

PMID:
31387885
6.

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].

Loriot MA, Masskouri F, Carni P, Le Malicot K, Seitz JF, Michel P, Legoux JL, Bouché O, André T, Faroux R, Delaloge S, Malka D, Guigay J, Thariat J, Thomas F, Barin-Le-Guellec C, Ciccolini J, Boyer JC, Étienne-Grimaldi MC.

Bull Cancer. 2019 Sep;106(9):759-775. doi: 10.1016/j.bulcan.2019.04.013. Epub 2019 Jun 25. French.

PMID:
31253356
7.

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.

Haddad R, Concha-Benavente F, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL.

Cancer. 2019 Sep 15;125(18):3208-3218. doi: 10.1002/cncr.32190. Epub 2019 Jun 27.

8.

Approach to the Patient with Recurrent/Metastatic Disease.

Guigay J, Sâada-Bouzid E, Peyrade F, Michel C.

Curr Treat Options Oncol. 2019 Jun 25;20(8):65. doi: 10.1007/s11864-019-0664-z. Review.

PMID:
31240480
9.

Evaluation of the information given to patients undergoing total pharyngolaryngectomy and quality of life: a prospective multicentric study.

Bozec A, Schultz P, Gal J, Chamorey E, Chateau Y, Dassonville O, Poissonnet G, Peyrade F, Saada E, Guigay J, Benezery K, Leysalle A, Santini L, Giovanni A, Messaoudi L, Fakhry N.

Eur Arch Otorhinolaryngol. 2019 Sep;276(9):2531-2539. doi: 10.1007/s00405-019-05513-6. Epub 2019 Jun 20.

PMID:
31240456
10.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.

Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML.

Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.

PMID:
31239321
11.

Treatment of inoperable elderly head and neck cancer patients.

Guigay J, Le Caer H, Ortholan C, Aupérin A, Michel C, Mertens C.

Curr Opin Oncol. 2019 May;31(3):152-159. doi: 10.1097/CCO.0000000000000526.

PMID:
30985496
12.

Things are changing for head and neck squamous cell carcinomas.

Guigay J.

Curr Opin Oncol. 2019 May;31(3):121. doi: 10.1097/CCO.0000000000000524. No abstract available.

PMID:
30985495
13.

Molecular genetics of head and neck squamous cell carcinoma.

Saada-Bouzid E, Peyrade F, Guigay J.

Curr Opin Oncol. 2019 May;31(3):131-137. doi: 10.1097/CCO.0000000000000536.

PMID:
30893149
14.

Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.

Saada-Bouzid E, Peyrade F, Guigay J.

Curr Opin Oncol. 2019 May;31(3):146-151. doi: 10.1097/CCO.0000000000000522.

PMID:
30893146
15.

Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.

Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, Guigay J, Cupissol D, Delord JP, Lallemant B, Alfonsi M, Aubry K, Mazel M, Becher F, Perriard F, Chatelut E, Thomas F.

Br J Clin Pharmacol. 2019 Jun;85(6):1357-1366. doi: 10.1111/bcp.13907. Epub 2019 Apr 13.

PMID:
30811063
16.

The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again.

Hofman P, Ayache N, Barbry P, Barlaud M, Bel A, Blancou P, Checler F, Chevillard S, Cristofari G, Demory M, Esnault V, Falandry C, Gilson E, Guérin O, Glaichenhaus N, Guigay J, Ilié M, Mari B, Marquette CH, Paquis-Flucklinger V, Prate F, Saintigny P, Seitz-Polsky B, Skhiri T, Van Obberghen-Schilling E, Van Obberghen E, Yvan-Charvet L.

Cancers (Basel). 2019 Feb 21;11(2). pii: E250. doi: 10.3390/cancers11020250.

17.

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.

Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A, Caballero C, Fortpied C, Bogaerts J, Govaerts AS, Staelens D, Raveloarivahy T, Rodegher L, Laes JF, Saada-Bouzid E, Machiels JP.

Ann Oncol. 2018 Dec 1;29(12):2313-2327. doi: 10.1093/annonc/mdy452.

18.

[Hypofractionad radiotherapy for elderly with head and neck cancer].

Ortholan C, Auperin A, Mertens C, Le Caer H, Guigay J.

Cancer Radiother. 2018 Oct;22(6-7):640-643. doi: 10.1016/j.canrad.2018.06.008. Epub 2018 Aug 11. Review. French.

PMID:
30108013
19.

Predicting early death in older adults with cancer.

Boulahssass R, Gonfrier S, Ferrero JM, Sanchez M, Mari V, Moranne O, Rambaud C, Auben F, Hannoun Levi JM, Bereder JM, Bereder I, Baque P, Turpin JM, Frin AC, Ouvrier D, Borchiellini D, Largillier R, Sacco G, Delotte J, Arlaud C, Benchimol D, Durand M, Evesque L, Mahamat A, Poissonnet G, Mouroux J, Barriere J, Benizri E, Piche T, Guigay J, Francois E, Guerin O.

Eur J Cancer. 2018 Sep;100:65-74. doi: 10.1016/j.ejca.2018.04.013. Epub 2018 Jun 29.

PMID:
30014882
20.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.

Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.

21.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.

Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4.

22.

Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.

Tardy MP, Di Mauro I, Ebran N, Refae S, Bozec A, Benezery K, Peyrade F, Guigay J, Sudaka-Bahadoran A, Badoual C, Pedeutour F, Saada-Bouzid E.

Oral Oncol. 2018 May;80:104-107. doi: 10.1016/j.oraloncology.2018.04.001. Epub 2018 Apr 7. No abstract available.

PMID:
29631799
23.

A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02).

Frikha M, Auperin A, Tao Y, Elloumi F, Toumi N, Blanchard P, Lang P, Sun S, Racadot S, Thariat J, Alfonsi M, Tuchais C, Cornely A, Moussa A, Guigay J, Daoud J, Bourhis J; GORTEC.

Ann Oncol. 2018 Mar 1;29(3):731-736. doi: 10.1093/annonc/mdx770.

PMID:
29236943
24.

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.

Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels JH.

Ann Oncol. 2017 Oct 1;28(10):2526-2532. doi: 10.1093/annonc/mdx344.

25.

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03.

Fayette J, Guigay J, Le Tourneau C, Degardin M, Peyrade F, Neidhardt EM, Sablin MP, Even C, Orlandini F, Juzyna B, Bellera C.

Oncotarget. 2017 Mar 4;8(31):51830-51839. doi: 10.18632/oncotarget.15901. eCollection 2017 Aug 1.

26.

[Reirradiation of head and neck cancers].

Doyen J, Lam Cham Kee D, Krebs L, Guigay J, Dassonville O, Peyrade F, Poissonnet G, Saâda-Bouzid E, Sudaka A, Bozec A, Bénézery K.

Cancer Radiother. 2017 Oct;21(6-7):521-526. doi: 10.1016/j.canrad.2017.07.023. Epub 2017 Aug 18. Review. French.

PMID:
28826697
27.

Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study.

Marciello F, Mercier O, Ferolla P, Scoazec JY, Filosso PL, Chapelier A, Guggino G, Monaco R, Grimaldi F, Pizzolitto S, Guigay J, de Latour BR, Giuffrida D, Longchampt E, de Montpreville VT, Fadel E, Colao A, Planchard D, Papotti M, Faggiano A, Baudin E.

Neuroendocrinology. 2018;106(3):264-273. doi: 10.1159/000480015. Epub 2017 Aug 17.

PMID:
28813709
28.

[A French multicenter research program for a personalized treatment of elderly head and neck cancer patient].

Guigay J, Mertens C, Le Caer H, Michel C, Ortholan C, Aupérin A.

Bull Cancer. 2017 Sep;104(9):816-819. doi: 10.1016/j.bulcan.2017.06.013. Epub 2017 Aug 7. French. No abstract available.

PMID:
28797481
29.

Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.

Lecomte P, Binquet C, Le Bras M, Tabarin A, Cardot-Bauters C, Borson-Chazot F, Lombard-Bohas C, Baudin E, Delemer B, Klein M, Vergès B, Aparicio T, Cosson E, Beckers A, Caron P, Chabre O, Chanson P, Du Boullay H, Guilhem I, Niccoli P, Rohmer V, Guigay J, Vulpoi C, Scoazec JY, Goudet P.

World J Surg. 2018 Jan;42(1):143-152. doi: 10.1007/s00268-017-4135-z.

PMID:
28785839
30.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J.

Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.

31.

NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?

Falk AT, Heeke S, Hofman V, Lespinet V, Ribeyre C, Bordone O, Poudenx M, Otto J, Garnier G, Castelnau O, Guigay J, Leroy S, Marquette CH, Hofman P, Ilié M.

Expert Rev Anticancer Ther. 2017 Aug;17(8):681-685. doi: 10.1080/14737140.2017.1331736. Epub 2017 May 22.

PMID:
28511612
32.

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J, Loirat D, Peyrade F, Alt M, Gal J, Le Tourneau C.

Ann Oncol. 2017 Jul 1;28(7):1605-1611. doi: 10.1093/annonc/mdx178.

PMID:
28419181
33.

Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance.

Guigay J, Even C, Mayache-Badis L, Debbah M, Saada-Bouzid E, Tao Y, Deschamps F, Janot F, Lezghed N, Michel C.

Oral Oncol. 2017 May;68:114-118. doi: 10.1016/j.oraloncology.2017.03.009. Epub 2017 Mar 24.

PMID:
28347701
34.

Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.

Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A, Leboulleux S, Déandréis D, Hadoux J, Ducreux M, Duvillard P, Adam J, Scoazec JY, Baudin E, Planchard D.

Eur J Cancer. 2017 Apr;75:259-267. doi: 10.1016/j.ejca.2016.11.034. Epub 2017 Feb 27.

PMID:
28242503
35.

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML.

N Engl J Med. 2016 Nov 10;375(19):1856-1867. Epub 2016 Oct 8.

36.

Evaluation of the information given to patients undergoing head and neck cancer surgery using the EORTC QLQ-INFO25 questionnaire: A prospective multicentric study.

Bozec A, Schultz P, Gal J, Chamorey E, Chateau Y, Dassonville O, Poissonnet G, Santini J, Peyrade F, Saada E, Guigay J, Benezery K, Leysalle A, Santini L, Giovanni A, Messaoudi L, Fakhry N.

Eur J Cancer. 2016 Nov;67:73-82. doi: 10.1016/j.ejca.2016.08.005. Epub 2016 Sep 9.

PMID:
27616438
37.

Dynamical focusing by bent, asymmetrically cut perfect crystals in Laue geometry.

Guigay JP, Ferrero C.

Acta Crystallogr A Found Adv. 2016 Jul 1;72(Pt 4):489-99. doi: 10.1107/S2053273316006549. Epub 2016 Jun 29.

PMID:
27357851
38.

Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.

Walter T, Planchard D, Bouledrak K, Scoazec JY, Souquet PJ, Dussol AS, Guigay J, Hervieu V, Berdelou A, Ducreux M, Arpin D, Lombard-Bohas C, Baudin E.

Lung Cancer. 2016 Jun;96:68-73. doi: 10.1016/j.lungcan.2016.03.018. Epub 2016 Mar 31.

PMID:
27133753
39.

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.

Clement PM, Gauler T, Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Cohen EE, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Vermorken JB; LUX-H&N 1 investigators.

Ann Oncol. 2016 Aug;27(8):1585-93. doi: 10.1093/annonc/mdw151. Epub 2016 Apr 15.

40.

Gauging low-dose X-ray phase-contrast imaging at a single and large propagation distance.

Hofmann R, Schober A, Hahn S, Moosmann J, Kashef J, Hertel M, Weinhardt V, Hänschke D, Helfen L, Sánchez Salazar IA, Guigay JP, Xiao X, Baumbach T.

Opt Express. 2016 Feb 22;24(4):4331-48.

PMID:
26907079
41.

Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors.

Bozec A, Benezery K, Ettaiche M, Chamorey E, Vandersteen C, Dassonville O, Poissonnet G, Riss JC, Hannoun-Lévi JM, Chand ME, Leysalle A, Saada E, Guigay J, Sudaka A, Demard F, Santini J, Peyrade F.

Eur Arch Otorhinolaryngol. 2016 Oct;273(10):3299-306. doi: 10.1007/s00405-016-3919-3. Epub 2016 Feb 9.

PMID:
26858198
42.

French Society of ENT (SFORL) guidelines for care pathway organization in head and neck oncology (short version). Early management of head and neck cancer.

Cuny F, Babin E, Lacau-Saint-Guily J, Baujat B, Bensadoun R, Bozec A, Chevalier D, Choussy O, Deneuve S, Fakhry N, Guigay J, Makeieff M, Merol JC, Mouawad F, Pavillet J, Rebiere C, Righini C, Sostras MC, Tournaille M, Vergez S; SFORL work group.

Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Sep;132(4):205-8. doi: 10.1016/j.anorl.2015.06.007. Epub 2015 Jul 13.

43.

Organization of primary care pathway in head and neck oncology (short version): Organization of chemotherapy in head and neck oncology.

Pavillet J, Guigay J, Lacau Saint-Guily J, Righini CA; SFORL work group.

Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Sep;132(4):209-12. doi: 10.1016/j.anorl.2015.06.008. Epub 2015 Jul 13.

44.

Guidelines (short version) of the French Otorhinolaryngology - Head and Neck Surgery Society (SFORL) on patient pathway organization in ENT: The therapeutic decision-making process.

Deneuve S, Babin E, Lacau-St-Guily J, Baujat B, Bensadoun RJ, Bozec A, Chevalier D, Choussy O, Cuny F, Fakhry N, Guigay J, Makeieff M, Merol JC, Mouawad F, Pavillet J, Rebiere C, Righini CA, Sostras MC, Tournaille M, Vergez S.

Eur Ann Otorhinolaryngol Head Neck Dis. 2015 Sep;132(4):213-5. doi: 10.1016/j.anorl.2015.06.006. Epub 2015 Jun 29.

45.

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.

Guigay J, Fayette J, Dillies AF, Sire C, Kerger JN, Tennevet I, Machiels JP, Zanetta S, Pointreau Y, Bozec Le Moal L, Henry S, Schilf A, Bourhis J.

Ann Oncol. 2015 Sep;26(9):1941-7. doi: 10.1093/annonc/mdv268. Epub 2015 Jun 24.

PMID:
26109631
46.

Integrating genomics in head and neck cancer treatment: Promises and pitfalls.

Thariat J, Vignot S, Lapierre A, Falk AT, Guigay J, Van Obberghen-Schilling E, Milano G.

Crit Rev Oncol Hematol. 2015 Sep;95(3):397-406. doi: 10.1016/j.critrevonc.2015.03.005. Epub 2015 Apr 18. Review.

PMID:
25979769
47.

Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer.

Levy A, De Felice F, Bellefqih S, Guigay J, Deutsch E, Nguyen F, Blanchard P, Tao Y.

Head Neck. 2016 Apr;38 Suppl 1:E905-10. doi: 10.1002/hed.24125. Epub 2015 Jul 15.

PMID:
25974356
48.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators.

Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16.

PMID:
25892145
49.

Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.

Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P, Berdelou A, Loriot Y, Duvillard P, Chougnet CN, Déandréis D, Schlumberger M, Borget I, Ducreux M, Baudin E.

Endocr Relat Cancer. 2015 Jun;22(3):289-98. doi: 10.1530/ERC-15-0075. Epub 2015 Mar 13.

PMID:
25770151
50.

Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells.

Mrizak D, Martin N, Barjon C, Jimenez-Pailhes AS, Mustapha R, Niki T, Guigay J, Pancré V, de Launoit Y, Busson P, Moralès O, Delhem N.

J Natl Cancer Inst. 2014 Dec 12;107(1):363. doi: 10.1093/jnci/dju363. Print 2015 Jan.

PMID:
25505237

Supplemental Content

Loading ...
Support Center